On why we need to provide BioMedical/Therapeutic/Pharma/Clinical Ideas to Professors/Physicians/Faculties/Researchers
You may ask why we need to provide ideas to Scientists/Professors/Physicians/Medical Doctors/Pharmacists/Researchers/Clinicians, as they are supposed to be generating ideas for their own work.
Let me give you a few examples.
- Prof. Thistlethwaite PA’s research team, from University of California, USA, has published a paper, namely, “Notch3 signaling promotes the development of pulmonary arterial hypertension” in the journal Nature medicine [the number 1 research journal in “General Medicine” with an I.F of 28.054] in 2009. Although it is going to be nearly 6 years since this paper was published, there are not even a few follow up papers on the promising findings published in the high profile journal. On the other hand, GBMD has recently gone through this paper and published > 55 therapeutic ideas, with the reproducibility rate of 90%. This suggests: (1) that there is more room to do further work on the findings by Prof. Thistlethwaite PA’s research team, but it has not been done; and (2) that neither Prof. Thistlethwaite PA’s research team nor the scientists who work in the field of “Notch signaling and hypertension” had no idea—or, no time to generate ideas— related to the study published in Nature medicine. This signifies the importance and the necessity of our unique scientific service which is being offered to the scientific institutions around the globe, especially to the Physicians/Scientists/professors/researchers/Clinicians/Pharmacists in low profile universities, where publishing a research paper in a high profile journal, such as Nature, science, cell etc., is still a nightmare/distant dream
- We generate high quality ideas based on the “experimental/research papers” published in high profile journals. For instance, Prof. Dimmler, Director, from the Institute for cardiovascular regeneration, Germany, has published a paper [ MicroRNA-34a regulates cardiac ageing and function ] in the journal “Nature”. Based on that paper, I have published > 140 ideas within a span of nearly one year. To publish a paper in a high profile journal, it takes about 3 to 4 years. I have, on the other hand, published >140 ideas, with the reproducibility rate of 90%, related to the paper published in Nature–the number 1 research journal in Science–within a year, a task that was previously achieved by no other biologist in the world. Therefore, it is not surprising that our ideas were viewed by the best institutions around the globe.
- Prof. Dr. Richard I. Gregory and his co-workers from Harvard Medical School, Boston, MA, USA; and Harvard Stem Cell Institute, Boston, MA, USA had reported in the prestigious number one bio-journal Cell (27 February 2014) that “Hippo Signalling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer.” Based on that paper, I have published 41 ideas within a span of one year.
- Prof Dominic J. Withers and his co-workers from Institute of Healthy Ageing, University College London had reported in the prestigious journal Science (2 October 2009) that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” Based on that paper, we have published 42 ideas.
- If GBMD did not publish these ideas on its portal, for the sake of international science community, then, for instance, Prof. Richard I. Gregory and his co-workers or Prof Dominic J. Withers or other scientists who’re very familiar with their own work would have done the follow up work. And to see a follow up of their work in high profile journals, it will take another 3-4 years. Given that any individual research team in the globe is limited by the number of people who work for them, the research progress will be slow. As a result, drugs discovery, which largely depends on detailed mechanistic insights on the available drug targets, process will be delayed. This is where our unique scientific service plays a significant role in Bio-Medical/Therapeutic/Clinical/Pharma Science. That is, by letting the international scientific community to know the future research directions or disease targets unreported in the biomedical literature, as soon as a good research paper is published in high profile journals such as Nature, Cell, Science etc.